SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Moertel CG. Chemotherapy of gastrointestinal cancer. Clin Gastroenterol. 1976; 5: 777793.
  • 2
    Hansen R, Quebbeman E, Ritch P, et al. Continuous 5-fluorouracil (5FU) infusion in carcinoma of the pancreas: a phase II study. Am J Med Sci. 1988; 295: 9193.
  • 3
    DeCaprio JA, Mayer RJ, Gonin R, et al. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. J Clin Oncol. 1991; 9: 21282133.
  • 4
    Ahlgren JD. Chemotherapy for pancreatic carcinoma. Cancer. 1996; (3 Suppl ): 654663.
  • 5
    Cullinan SA, Moertel CG, Fleming TR, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Fluorouracil vs fluorouracil and doxorubicin vs fluorouracil, doxorubicin, and mitomycin. JAMA. 1985; 253: 20612067.
  • 6
    Oster MW, Gray R, Panasci L, et al. Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM). Cancer. 1986; 57: 2933.
  • 7
    Cullinan S, Moertel CG, Wieand HS, et al. A phase III trial on the therapy of advanced pancreatic carcinoma. Evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer. 1990; 65: 22072212.
  • 8
    Kelsen D, Hudis C, Niedzwiecki D, et al. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer. 1991; 68: 965969.
  • 9
    Andersen JS, Burris HA, Casper E, et al. Development of a new system for assessing clinical benefit for patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol. 1994; 13: A1600..
  • 10
    Casper ES, Green MR, Kelsen DP, et al. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs. 1994; 12: 2934.
  • 11
    Carmichael J, Fink U, Russell RC, et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer. 1996; 73: 101105.
  • 12
    Rothenberg ML, Moore MJ, Cripps MC, et al. A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol. 1996; 7: 347353.
  • 13
    Burris HA 3rd, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol. 1997; 15: 24032413.
  • 14
    Storniolo AM, Enas NH, Brown CA, et al. An investigational new drug treatment program for patients with gemcitabine: results for over 3000 patients with pancreatic carcinoma. Cancer. 1999; 85: 12611268.
  • 15
    Moore MJ, Hamm J, Eisenberg P, et al. A comparison between gemcitabine (GEM) and the matrix metalloproteinase (MMP) inhibitor BAY12-9566 (9566) in patients (PTS) with advanced pancreatic cancer. Proc Am Soc Clin Oncol. 2000; 19: A930.
  • 16
    Oettle H, Pelzer U, Hochmuth K, et al. Phase I trial of gemcitabine (Gemzar), 24 h infusion 5-fluorouracil and folinic acid in patients with inoperable pancreatic cancer. Anticancer Drugs. 1999; 10: 699704.
  • 17
    Oettle H, Arning M, Pelzer U, et al. Phase II trial of gemcitabine in combination with 5-fluorouracil (24-hour) and folinic acid in patients with chemonaive advanced pancreatic cancer. Ann Oncol. 2000; 11: 12671272.
  • 18
    Polyzos A, Tsavaris N, Kosmas C, et al. A phase II study of gemcitabine (GEM) plus 5-fluorouracil (5-FU) modulated by leucovorin (LV) for advanced pancreatic cancer. Proc Am Soc Clin Oncol. 2000; 19: A1229.
  • 19
    Louvet C, Andre T, Hammel P. Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM). Ann Oncol. 2001; 12: 675679.
  • 20
    Mousseau M, Rebischung C, Garnier C, et al. Phase I/II study in advanced pancreatic adenocarcinoma (APA) and carcinoma of unknown primary (CUP): a combination of leucovorin (LV), 5-FU bolus and infusion, gemcitabine (GEM) and oxaliplatin (L-OHP) (FOLFU GEMOX REGIMEN). Proc Am Soc Clin Oncol. 2000; 19: A913.
  • 21
    Gutzler F, Moehler M, Hosch WP, et al. A phase I study of gemcitabine (GEM) in combination, with five days 5-fluorouracil (5-FU) and folinic acid (FA) in patients with advanced adenocarcinoma of pancreas or bile duct. Proc Am Soc Clin Oncol. 1999; 18: A1097.
  • 22
    Jovtis S, Marantz A, Almira E, et al. Phase II trial of gemcitabine (GEM), 5-fluorouracil and leucovorin (LV) in advanced pancreatic cancer (APC). Eur J Cancer. 1999; 35: A586.
  • 23
    Castellano D, Paz-Ares L, Pronk L, et al. A phase I/II clinical and pharmacologic study of dose-escalating and dose-sequencing of administration of gemcitabine (G) and folinic acid (FA)/fluorouracil (FU) in advanced pancreatic cancer (APC). Proc Am Soc Clin Oncol. 2000; 19: A1133.
  • 24
    Lencioni M, Falcone A, Masi L, et al. Phase I-II study of gemcitabine (GEM) in combination with 24 hours continuous infusion (CI) of 5-fluorouracil (5-FU) and L-leucovorin (LV) in patients (pts) with advanced pancreatic carcinoma (APC). Proc Ann Oncol 2000; 11 (Suppl 4): A289.
  • 25
    Hidalgo M, Castellano D, Paz-Ares L, et al. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol. 1999; 17: 585592.
  • 26
    Borner MM, Mauerer CA, Friess H, et al. Gemcitabine (GEM) and continuous infusion fluorouracil (CIF): a phase II study in advanced pancreatic cancer (APC). Ann Oncol. 1998; 9: A241 P.
  • 27
    Anchisi S, Delaloye B, Petite J, et al. Gemcitabine (Gem) and continuous infusion 5-FU (Cif) is active and well tolerated in advanced or metastatic pancreatic cancer. Proc Am Soc Clin Oncol. 2000; 19: A1280H.
  • 28
    Rodríguez-Lescure A, Carrato A, Massutí B, et al. Phase I-II study of gemcitabine (GEM) and weekly 48-hour continuous infusion (CI) of high-dose 5-fluorouracil (5-FU) in advanced exocrine pancreatic cancer (APC). Proc Am Soc Clin Oncol. 1999; 18: A1145.
  • 29
    Shulman KL, Kindler HL, Lad TE, et al. Phase II study of gemcitabine (G) and continuous intravenous infusion (CIV) 5-fluorouracil (5-FI) in advanced pancreatic cancer (PC): a University of Chicago phase II consortium study. Proc Am Soc Clin Oncol. 2000; 19: A1126.
  • 30
    Riedel C, Wein A, Wehler M, et al. High-dose 5-fluorouracil (FU) 24-h-infusion with gemcitabine (GEM): tolerable and efficient in palliative outpatient treatment of pancreatic cancer. Proc Am Soc Clin Oncol. 2000; 19: A1248.
  • 31
    Cascinu S, Silva RR, Barni S, et al. A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br J Cancer. 1999; 80: 15951598.
  • 32
    Berlin JD, Adak S, Vaughn DJ, et al. A phase II study of gemcitabine and 5-fluorouracil in metastatic pancreatic cancer: an Eastern Cooperative Oncology Group Study (E3296). Oncology. 2000; 58: 215218.
  • 33
    Pastorelli D, Pedrazzoli S, Sperti C, et al. Phase II trial with gemcitabine (GEM) + 5-fluorouracil (5-FU) in advanced pancreatic cancer (APC). Proc Am Soc Clin Oncol. 2000; 19: A1110.
  • 34
    de Gusmão CBRA, Murad AM, Scalabrini-Neto AO, et al. Phase II trial of the use of gemcitabine (G) and 5-fluorouracil (5-FU) in the treatment of advanced pancreatic (APC) and biliary tract (ABTC) adenocarcinoma. Proc Am Soc Clin Oncol. 1998; 17: A1116.
  • 35
    Tarantani P, Corsi DC, Cassano A, et al. Weekly gemcitabine (GEM) and 5-fluorouracil (5-FU) in pancreatic carcinoma. Phase I-II study. Eur J Cancer. 1999; 35: A582.
  • 36
    Kurtz JE, Kohser F, Negrier S, et al. Gemcitabine and protracted 5-FU for advanced pancreatic cancer. A phase II study. Hepatogastroenterology. 2000; 47: 14501453.
  • 37
    Rauch DP, Maurer CA, Aebi S, et al. Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer. Oncology. 2001; 60: 4348.
  • 38
    Alabiso O, Buosi R, Clerico M, et al. Preliminary results of a phase II study with gemcitabine and continuous infusion 5FU in patients with advanced or metastatic pancreatic cancer. Proc Am Soc Clin Oncol. 2001; 20: A2331.
  • 39
    Matano E, Tagliaferri P, Libroia A, et al. Gemcitabine combined with continuous infusion 5-fluorouracil in advanced and symptomatic pancreatic cancer: a clinical benefit-oriented phase II study. Br J Cancer. 2000; 82: 17721775.
  • 40
    Di Costanzo F, Sdrobolini A, Carlini P, et al. Gemcitabine (GEM) alone or in combination with 5-FU continuous infusion (CI) in the treatment of advanced pancreatic cancer (APC): a GOIRC randomized phase II trial. Proc Am Soc Clin Oncol. 2001; 20: A612.
  • 41
    Hermann R, Borner M, Morant R, et al. Combining gemcitabine (GEM) and capecitabine (CAP) in advanced pancreatic cancer: results of a phase I trial. Proc Am Soc Clin Oncol. 2000; 19: A1038.
  • 42
    Zanon C, Alabiso O, Grosso M, et al. Intra-arterial continuous infusion for treatment of pancreatic and biliary tract cancer. Int J Pancreatol. 2000; 27: 225233.
  • 43
    Cascinu S, Frontini L, Labianca R, et al. A combination of a fixed dose rate infusion of gemcitabine associated to a bolus 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Ann Oncol. 2000; 11: 13091311.
  • 44
    Berlin J, Catalano P, Thomas J, et al. A phase III study of gemcitabine in combination with 5-FU vs. gemcitabine alone in patients with advanced pancreatic carcinoma (E2297): an Eastern Cooperative Oncology Group (ECOG) trial. Proc Am Soc Clin Oncol. 2001; 20: A505.
  • 45
    Murad AM, de Gusmão CBRA, Scalabrini-Neto AO. Phase II trial of the use of gemcitabine and 5-fluorouracil (5-FU) in the treatment of advanced pancreatic (APC) and biliary tract (ABTC) adenocarcinoma. Final report. Ann Oncol. 2000; 11 (Suppl 4): A302P.
  • 46
    Geuenich S, Wilkowski R, Vehling-Kaiser U. Gemcitabine and high-dose 5-fluorouracil/folinic acid: a phase I study. Proc Am Soc Clin Oncol. 2001; 20: A2271.
  • 47
    Garnier C, Rebischung C, Chirpaz E, et al. Phase II study of a combination with leucovorin (LV), 5-FU bolus and infusion (FU), gemcitabine (GEM) and oxaliplatin (LOHP) (FOLFU GEMOX regimen) in locally advanced (LA) and metastatic (M) pancreatic carcinoma (APC). Proc Am Soc Clin Oncol. 2001; 19: A620.
  • 48
    De Castro J, López Álvarez Mp, Rodríguez Jaráiz A, et al. Phase II trial of gemcitabine and UFT modulated by leucovorin in patients with advanced pancreatic cancer. Proc Am Soc Clin Oncol. 2000; 19: A1040.
  • 49
    Kozuch P, Areneo M, Homel P, et al. Biweekly sequential gemcitabine, 5-FU (5-fluorouracil), LV (leucovorin) and cisplatin (GFP): a highly active novel combination for metastatic adenocarcinoma of the exocrine pancreas (MPAC). Proc Am Soc Clin Oncol. 2001; 20: A617.
  • 50
    Colucci G, Riccardi F, Giuliani F, et al. Randomized trial of gemcitabine (GEM) alone or with cisplatin (CDDP) in the treatment of advanced pancreatic cancer (APC): a phase II multicenter study of the Southern Italy Oncology Group. Proc Am Soc Clin Oncol. 1999; 18: A961.
  • 51
    Colucci G, Giuliani F, Maiello E, et al. Cisplatin (CCDP), gemcitabine (GEM), folinic acid (FA) and fluorouracil (FU) in the treatment of locally advanced inoperable and/or metastatic pancreatic adenocarcinoma: a phase II study of the Southern Italian Oncology Group (GOIM). Ann Oncol. 2000; 11 (Suppl 4): 69.
  • 52
    Philip PA, Zalupski MM, Vaitkevicius VK, et al. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma. Cancer. 2001; 92: 569577.
  • 53
    Philip PA, Shields A, Zalupski M, et al. Gemcitabine, cisplatin and 5-fluorouracil in advanced pancreas cancer. Proc Am Soc Clin Oncol. 2001; 20: A2341.
  • 54
    Maurel J, García López JL, León A, et al. Phase II trial of gemcitabine (GEM) and 48-hour continuous infusion (CI) of 5-fluorouracil (5-FU) as first-line treatment for patients with locally advanced and metastatic exocrine pancreatic cancer (PC). Proc Am Soc Clin Oncol. 2001; 20: A2290.